COMy 2020 | The evolving role of IMiDs
Xavier Leleu
• 30 Sep 2020
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the importance of immunomodulatory imide drugs (IMiDs) in multiple myeloma treatment. Offsprings of thalidomide, such as lenalidomide and pomalidomide, are very effective treatments for transplant and non-transplant eligible patients. Lenalidomide is one of the best foundations for drug combinations; however, there are still areas for improvement. Some patients treated with lenalidomide become refractory. Dr Leleu also discusses CC-92480 and iberdomide. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
